AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:28 2024-05-14 am EDT			5-day change	1st Jan Change
12,246 ^GBX	-0.58%		+1.06%	+15.53%

02:05pm	ASTRAZENECA : Buy rating from JP Morgan	ZD
May. 13	AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study	MT

ASTRAZENECA : Jefferies gives a Neutral rating

April 19, 2022 at 07:40 am EDT

Peter Welford from Jefferies retains his Neutral opinion on the stock. The target price has been raised to GBX 9500 from GBX 8800.

Latest news about AstraZeneca PLC

ASTRAZENECA : Buy rating from JP Morgan	08:05am	ZD
AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study	May. 13	MT
AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study	May. 13	MT
AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study	May. 13	MT
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update	May. 13	DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update	May. 13	DJ
Cinven to explore $3 billion sale of software maker Jaggaer, sources say	May. 13	RE
Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France	May. 13	MT
France Secures Billions at Foreign Investment Summit	May. 13	DJ
France gets $16 billion of foreign investments as part of 'Choose France' event	May. 13	RE
AstraZeneca Pledges $388 Million Investment at French Site	May. 12	MT
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France	May. 12	RE
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	May. 08	MT
AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement	May. 08	MT
AstraZeneca to Reportedly Withdraw COVID-19 Vaccine Amid Cooling Demand	May. 08	MT
SERUM INSTITUTE OF INDIA ON ASTRAZENECA'S WITHDRAWAL OF VAXZERVR…	May. 08	RE
Jefferies Lifts AstraZeneca PT, Maintains Hold Rating	May. 08	MT
ASTRAZENECA : Jefferies sticks Neutral	May. 08	ZD
AstraZeneca says withdraws Covid vaccine "for commercial reasons"	May. 08	AN
UBS raises Centrica to 'buy' from 'neutral	May. 08	AN
AstraZeneca lifts FTSE 100 to record high; BOE rate decision on tap	May. 08	RE
AstraZeneca to Remove COVID-19 Jab from EU Markets Due to Commercial Reasons	May. 07	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society Conference - Abstarct Number - P297

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.6 USD

Average target price

166.8 USD

Spread / Average Target

+7.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+15.53%	240B
ELI LILLY AND COMPANY	+30.15%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.75%	364B
MERCK & CO., INC.	+17.66%	327B
ABBVIE INC.	+3.60%	285B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+7.45%	165B
PFIZER, INC.	-1.85%	161B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Jefferies gives a Neutral rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals